Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 125

1.

Limitations of basing screening policies on screening trials: The US Preventive Services Task Force and Prostate Cancer Screening.

Etzioni R, Gulati R, Cooperberg MR, Penson DM, Weiss NS, Thompson IM.

Med Care. 2013 Apr;51(4):295-300. doi: 10.1097/MLR.0b013e31827da979.

PMID:
23269114
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Counterpoint: Randomized trials provide the strongest evidence for clinical guidelines: The US Preventive Services Task Force and Prostate Cancer Screening.

Melnikow J, LeFevre M, Wilt TJ, Moyer VA.

Med Care. 2013 Apr;51(4):301-3. doi: 10.1097/MLR.0b013e31828a67d3.

PMID:
23481031
[PubMed - indexed for MEDLINE]
3.

Screening for prostate cancer.

Ilic D, Neuberger MM, Djulbegovic M, Dahm P.

Cochrane Database Syst Rev. 2013 Jan 31;1:CD004720. doi: 10.1002/14651858.CD004720.pub3. Review.

PMID:
23440794
[PubMed - indexed for MEDLINE]
4.

Randomized controlled screening trials for prostate cancer using prostate-specific antigen: a tale of contrasts.

Rove KO, Crawford ED.

World J Urol. 2012 Apr;30(2):137-42. doi: 10.1007/s00345-011-0799-4. Epub 2011 Nov 25. Review.

PMID:
22116599
[PubMed - indexed for MEDLINE]
5.

Response: Reading between the lines of cancer screening trials: using modeling to understand the evidence.

Etzioni R, Gulati R.

Med Care. 2013 Apr;51(4):304-6. doi: 10.1097/MLR.0b013e31828a7e1a.

PMID:
23481032
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).

Schröder FH.

Can J Urol. 2005 Feb;12 Suppl 1:2-6; discussion 92-3. Review.

PMID:
15780157
[PubMed - indexed for MEDLINE]
7.

Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial.

de Koning HJ, Auvinen A, Berenguer Sanchez A, Calais da Silva F, Ciatto S, Denis L, Gohagan JK, Hakama M, Hugosson J, Kranse R, Nelen V, Prorok PC, Schröder FH; European Randomized Screening for Prostate Cancer (ERSPC) Trial; International Prostate Cancer Screening Trials Evaluation Group.

Int J Cancer. 2002 Jan 10;97(2):237-44.

PMID:
11774270
[PubMed - indexed for MEDLINE]
8.

Screening for prostate cancer: the current evidence and guidelines controversy.

Gomella LG, Liu XS, Trabulsi EJ, Kelly WK, Myers R, Showalter T, Dicker A, Wender R.

Can J Urol. 2011 Oct;18(5):5875-83. Review.

PMID:
22018148
[PubMed - indexed for MEDLINE]
Free Article
9.

Risk stratification in prostate cancer screening.

Roobol MJ, Carlsson SV.

Nat Rev Urol. 2013 Jan;10(1):38-48. doi: 10.1038/nrurol.2012.225. Epub 2012 Dec 18. Review. Erratum in: Nat Rev Urol. 2013 May;10(5):248.

PMID:
23247693
[PubMed - indexed for MEDLINE]
10.

Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context.

Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, Feuer E, de Koning H.

J Natl Cancer Inst. 2009 Mar 18;101(6):374-83. doi: 10.1093/jnci/djp001. Epub 2009 Mar 10.

PMID:
19276453
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Prostate cancer specific survival in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.

Pinsky PF, Black A, Parnes HL, Grubb R, David Crawford E, Miller A, Reding D, Andriole G.

Cancer Epidemiol. 2012 Dec;36(6):e401-6. doi: 10.1016/j.canep.2012.08.008. Epub 2012 Sep 19.

PMID:
23000116
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Screening for prostate cancer: reflecting on the quality of evidence from the ERSPC and PLCO studies.

Ilic D.

Recent Results Cancer Res. 2014;202:65-71. doi: 10.1007/978-3-642-45195-9_8.

PMID:
24531779
[PubMed - indexed for MEDLINE]
13.

Prostate cancer screening: what we have learned from the PLCO and ERSPC trials.

La Rochelle J, Amling CL.

Curr Urol Rep. 2010 May;11(3):198-201. doi: 10.1007/s11934-010-0109-5. Review.

PMID:
20425627
[PubMed - indexed for MEDLINE]
14.

Early detection of prostate cancer: AUA Guideline.

Carter HB, Albertsen PC, Barry MJ, Etzioni R, Freedland SJ, Greene KL, Holmberg L, Kantoff P, Konety BR, Murad MH, Penson DF, Zietman AL.

J Urol. 2013 Aug;190(2):419-26. doi: 10.1016/j.juro.2013.04.119. Epub 2013 May 6.

PMID:
23659877
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates.

Gulati R, Mariotto AB, Chen S, Gore JL, Etzioni R.

J Clin Epidemiol. 2011 Dec;64(12):1412-7. doi: 10.1016/j.jclinepi.2011.06.011.

PMID:
22032753
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.

Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, Fouad MN, Isaacs C, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Ragard LR, Clapp JD, Rathmell JM, Riley TL, Hsing AW, Izmirlian G, Pinsky PF, Kramer BS, Miller AB, Gohagan JK, Prorok PC; PLCO Project Team.

J Natl Cancer Inst. 2012 Jan 18;104(2):125-32. doi: 10.1093/jnci/djr500. Epub 2012 Jan 6.

PMID:
22228146
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.

Pinsky PF, Blacka A, Kramer BS, Miller A, Prorok PC, Berg C.

Clin Trials. 2010 Aug;7(4):303-11. doi: 10.1177/1740774510374091. Epub 2010 Jun 22.

PMID:
20571134
[PubMed - indexed for MEDLINE]
18.

Prostate-specific antigen screening in the United States vs in the European Randomized Study of Screening for Prostate Cancer-Rotterdam.

Wever EM, Draisma G, Heijnsdijk EA, Roobol MJ, Boer R, Otto SJ, de Koning HJ.

J Natl Cancer Inst. 2010 Mar 3;102(5):352-5. doi: 10.1093/jnci/djp533. Epub 2010 Feb 8.

PMID:
20142584
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC).

Roobol MJ, Kerkhof M, Schröder FH, Cuzick J, Sasieni P, Hakama M, Stenman UH, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis L, Recker F, Berenguer A, Ruutu M, Kujala P, Bangma CH, Aus G, Tammela TL, Villers A, Rebillard X, Moss SM, de Koning HJ, Hugosson J, Auvinen A.

Eur Urol. 2009 Oct;56(4):584-91. doi: 10.1016/j.eururo.2009.07.018. Epub 2009 Jul 28.

PMID:
19660851
[PubMed - indexed for MEDLINE]
20.

Screening for Prostate Cancer with Prostate-Specific Antigen: What's the Evidence?

Marcus PM, Kramer BS.

Am Soc Clin Oncol Educ Book. 2012:96-100. doi: 10.14694/EdBook_AM.2012.32.96.

PMID:
24451716
[PubMed - in process]
Free Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk